» Articles » PMID: 16750389

Glioma Stem Cells: Evidence and Limitation

Overview
Specialty Oncology
Date 2006 Jun 6
PMID 16750389
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Gliomas, in particular the high-grade anaplastic glioma and glioblastoma multiforme (GBM), are manifested by morphological, genetic and phenotypic heterogeneity. Most of the studies hitherto have been performed on bulk glioma cells, with limited understanding on the origin and the relative contribution of particular glioma cell populations to glioma growth and progression. Recent studies have demonstrated the existence of a small fraction of glioma cells endowed with features of primitive neural progenitor cells and tumor-initiating function. Such cells have been defined as glioma stem cells. However, questions remain as to whether the currently identified glioma stem cells are the cell-of-origin for glioma initiation and progression, or the results of such processes. In this review, we discuss the current evidence and limitation in identifying glioma stem cells and the potential origin of glioma stem cells in the context of post-natal neural cell regeneration and their transformation mechanisms. The implication of these findings for glioma diagnosis and treatment will also be reviewed.

Citing Articles

Ferroptosis-Related Transcriptional Level Changes and the Role of CIRBP in Glioblastoma Cells Ferroptosis.

Yang Z, Zhang T, Zhu X, Zhang X Biomedicines. 2025; 13(1).

PMID: 39857625 PMC: 11761263. DOI: 10.3390/biomedicines13010041.


Regulatory Network of Methyltransferase-Like 3 in Stem Cells: Mechanisms and Medical Implications.

Zeng Y, Wang F, Li S, Song B Cell Transplant. 2024; 33:9636897241282792.

PMID: 39466679 PMC: 11528761. DOI: 10.1177/09636897241282792.


Prevalence and risk factors of early postoperative seizures in patients with glioma: A protocol for meta-analysis and systematic review.

Sun B, Lu W, Yu W, Tian Y, Wang P PLoS One. 2024; 19(4):e0301443.

PMID: 38574171 PMC: 10994364. DOI: 10.1371/journal.pone.0301443.


TGF-β-activated circRYK drives glioblastoma progression by increasing VLDLR mRNA expression and stability in a ceRNA- and RBP-dependent manner.

Wang Y, Wang B, Cao W, Xu X J Exp Clin Cancer Res. 2024; 43(1):73.

PMID: 38454465 PMC: 10921701. DOI: 10.1186/s13046-024-03000-3.


Inhibitor of Wnt receptor 1 suppresses the effects of Wnt1, Wnt3a and β‑catenin on the proliferation and migration of C6 GSCs induced by low‑dose radiation.

Yan Y, Cheng Y, Li Y, Jiao X, Liu Y, Cai H Oncol Rep. 2023; 51(2).

PMID: 38099414 PMC: 10777445. DOI: 10.3892/or.2023.8681.